Top

Published in:

01-02-2008 | Commentary

Tumor stromal barriers to the success of adoptive T cell therapy

Authors: Vy Phan, Mary L. Disis

Published in: Cancer Immunology, Immunotherapy | Issue 2/2008

Excerpt

Adoptive transfer of tumor competent T cells has long been studied as a therapeutic modality that may result in complete tumor eradication [1]. Indeed, T cells have the potential to home to all sites of metastatic disease no matter where the location and induce antigen-specific cell destruction. Theoretically, local clonal expansion of T cells in response to antigen will allow persistent killing over time until every cancer cell has been eradicated. No chemotherapeutic or biologic therapy developed to date has the ability to result in a persistent long lived anti-tumor effect. Unfortunately, the road to developing successful adoptive T cell therapy as a standard treatment for solid tumors has been littered with roadblocks. …

Cheever MA, Chen W (1997) Therapy with cultured T cells: principles revisited. Immunol Rev 157:177–194PubMedCrossRef

Leen AM, Rooney CM, Foster AE (2007) Improving T cell therapy for cancer. Annu Rev Immunol 25:243–265PubMedCrossRef

Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057–1061PubMedCrossRef

Chen A et al (2007) Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res 67(3):1291–1298PubMedCrossRef

Yee C et al (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99(25):16168–16173PubMedCrossRef

Dudley ME et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346–2457PubMedCrossRef

Morgan RA et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126–129PubMedCrossRef

Bernhard H, et al (2007) Adoptive transfer of autologous, HER-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother (in press)

Blankenstein T (2005) The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17(2):180–186PubMedCrossRef

10.

Ho WY et al (2003) Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3(5):431–437PubMedCrossRef

11.

Thanarajasingam U, et al (2007) Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 67(1):300–308PubMedCrossRef

12.

Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nat Med 10(3):294–298PubMedCrossRef

13.

Dunn GP et al (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6(7):722–729PubMedCrossRef

14.

Pages F et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666PubMedCrossRef

15.

Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964PubMedCrossRef

16.

Zhang L et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203–213PubMedCrossRef

17.

Chen Q et al (2006) Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 7(12):1299–1308PubMedCrossRef

18.

Skitzki J, Chen Q, Fisher D, Muhitch J, Wang W, Repasky E, Evans S (2007) Systemic thermal therapy improves effector cell trafficking to sites of tumor and clinical outcome. Abstract, STM Annual Meeting

19.

Zhang B et al (2007) Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204(1):49–55PubMedCrossRef

20.

Marijt WA et al (2003) Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 100(5):2742–2747PubMedCrossRef

21.

Bollard CM et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 200(12):1623–1633PubMedCrossRef

Title: Tumor stromal barriers to the success of adoptive T cell therapy
Authors: Vy Phan
Mary L. Disis
Publication date: 01-02-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 2/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0356-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2008

Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma

A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors

Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells

Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it?

MAGE-A3161–175 contains an HLA-DRβ4 restricted natural epitope poorly formed through indirect presentation by dendritic cells

CRMP5 antibodies in patients with small-cell lung cancer or thymoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer